Yahoo Finance 
Global Central Nervous System (CNS) Therapeutic Market Report, 2024: A Projected $215.19 Billion Opportunity by 2034 with with Asia-Pacific Gaining Momentum
Dublin, June 27, 2024 (GLOBE NEWSWIRE) -- The "Global Central Nervous System Therapeutic Market" report has been added to ResearchAndMarkets.com's offering.
The central nervous system (CNS) therapeutic market is experiencing a transformative growth period, with a forecasted Compound Annual Growth Rate (CAGR) of 6.07% from 2024 to 2034. Growth is primarily fueled by the rising global prevalence of CNS disorders, substantial investments in mental health, and a strategic focus on innovative therapies. An aging global population and supportive governmental initiatives are further driving market expansion.
Neurodegenerative Diseases and Antidepressants Lead the Market
The neurodegenerative diseases segment recorded the highest revenue within the market, attributed to the increasing incidence of Alzheimer’s, Parkinson’s, and related conditions. This growth is complemented by new avenues in research, greater awareness, and an emphasis on early diagnosis. Similarly, the antidepressants segment commanded a significant revenue share, mirroring the global increase in depression and mood disorders. Enhanced acceptance and understanding of mental health treatment, as well as the introduction of novel therapeutics, are key contributing factors.
Retail Pharmacies Dominate Distribution Channels; Specialty Clinics on the Rise
Retail pharmacies emerged as the top distribution channel, gaining from improved access, a spike in demand for CNS medications, and the proliferation of pharmacy chains. Concurrently, the specialty clinics segment is witnessing rapid growth due to heightened demand for specialized care for complex CNS disorders, coupled with advancements in treatment practices and substantial investments in healthcare infrastructure.
North America Stands at the Forefront with Asia-Pacific Gaining Momentum
With a robust healthcare system, significant R&D activities, and proactive mental health awareness, North America continues to lead in revenue share. In parallel, the Asia-Pacific region is expected to experience the fastest growth rate during the forecast period. Contributing factors include escalating healthcare investments, broader healthcare service access, and rising mental health awareness coinciding with demographic and lifestyle alterations.
Companies Featured
Pfizer Inc.
Johnson & Johnson
Novartis AG
Eli Lilly and Company
Merck & Co. Inc.
AbbVie Inc.
AstraZeneca PLC
Bristol Myers Squibb Company
GlaxoSmithKline PLC
Biogen Inc.
Teva Pharmaceutical Industries Ltd.
Otsuka Pharmaceutical Co. Ltd.
UCB S.A.
Eisai Co. Ltd.
Lundbeck A/S
For more information about this report visit https://www.researchandmarkets.com/r/9mgf1g
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
